Aptorum Group Ltd Cl A (APM)

$1.08 +0.14 (15.24%)
Market Cap 6.86M
Revenue (ttm) 0.00
Net Income (ttm) -4.27M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.26
Volume 212,600
Avg Vol 55,168
Day's Range N/A - N/A
Shares Out 6.35M
Stochastic %K 97%
Beta 0.17
Analysts Strong Buy
Price Target $80.00

Company Profile

Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylo...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 20 8092 9299
Address:
17 Hanover Square, London, United Kingdom
S2K_TP
S2K_TP Mar. 21 at 2:49 AM
$APM on watch next week đź‘€
0 · Reply
Jbjb90
Jbjb90 Mar. 20 at 8:53 PM
$APM ive rode this from below a dollar to 15 and from below a dollar to 4-5 over the last few years. Volume is starting to ramp up and the spam accounts are starting to flock and tag this symbol, we will hit 2-3 or more in the next few weeks
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 20 at 7:25 PM
$APM RSI: 76.92, MACD: 0.0116 Vol: 0.07, MA20: 0.82, MA50: 0.87 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
No_Face_character
No_Face_character Mar. 20 at 5:54 PM
$APM nice follow through
0 · Reply
Jbjb90
Jbjb90 Mar. 20 at 5:23 PM
$APM it wants to go, another 2-3+ run soon
0 · Reply
FoxyDreams
FoxyDreams Mar. 20 at 2:03 AM
•@SqueezeSharkie is on another level, outperforming 90% of traders on this platform. If you’re not following yet, you’re leaving value on the table. Takes 2 seconds and it’s free. 💎 $YDDL $FLD $YMAT $APM >>> on watch
0 · Reply
No_Face_character
No_Face_character Mar. 19 at 10:14 PM
$APM nice breakout here on the daily of a tight range, with good relative volume. watching.
0 · Reply
Jbjb90
Jbjb90 Mar. 19 at 6:29 PM
$APM this ones overdue for a run
0 · Reply
Jbjb90
Jbjb90 Mar. 16 at 3:39 PM
$APM https://www.stocktitan.net/news/APM/aptorum-group-and-diami-r-biosciences-announce-publication-of-micro-k3gy5kwhzw73.html
0 · Reply
DARKP00L
DARKP00L Mar. 10 at 12:32 PM
$APM 08:12 on Mar. 10 2026 Aptorum Group And DiamiR Biosciences Announce Publication Of Paper Showing Feasibility Of Detecting Glioblastoma Through Blood Plasma Tests #tradeideas
0 · Reply
Latest News on APM
Aptorum Group and DiamiR Biosciences Announce Publication of microRNA Glioblastoma Biomarker Study in Diagnostics in Collaboration with the University of Pennsylvania

Mar 10, 2026, 8:00 AM EDT - 11 days ago

Aptorum Group and DiamiR Biosciences Announce Publication of microRNA Glioblastoma Biomarker Study in Diagnostics in Collaboration with the University of Pennsylvania

Aptorum Group Announces a Collaboration Between DiamiR Biosciences and Instant NanoBiosensors (INB) to Validate INB's Automated APOE Testing Platform for Alzheimer's Disease

Feb 2, 2026, 8:00 AM EST - 6 weeks ago

Aptorum Group Announces a Collaboration Between DiamiR Biosciences and Instant NanoBiosensors (INB) to Validate INB's Automated APOE Testing Platform for Alzheimer's Disease

DiamiR Biosciences and Aptorum Group Announce Two Abstracts Accepted for Presentation at the Clinical Trials on Alzheimer's Disease (CTAD) 2025 Conference

Nov 19, 2025, 8:00 AM EST - 4 months ago

DiamiR Biosciences and Aptorum Group Announce Two Abstracts Accepted for Presentation at the Clinical Trials on Alzheimer's Disease (CTAD) 2025 Conference

Aptorum Group Limited Announces Up To $6 Million Registered Direct Offering

Oct 10, 2025, 9:54 AM EDT - 5 months ago

Aptorum Group Limited Announces Up To $6 Million Registered Direct Offering

As part of the planned merger with DiamiR Biosciences, Aptorum Group will expand its board and management team with seasoned executives

Oct 9, 2025, 8:55 AM EDT - 5 months ago

As part of the planned merger with DiamiR Biosciences, Aptorum Group will expand its board and management team with seasoned executives

Aptorum Group and DiamiR Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 5, 2025, 8:00 AM EDT - 7 months ago

Aptorum Group and DiamiR Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Why Is Nano-Cap Aptorum Stock Rallying On Thursday?

Aug 21, 2025, 11:39 AM EDT - 7 months ago

Why Is Nano-Cap Aptorum Stock Rallying On Thursday?

DiamiR Biosciences and Aptorum Group Announce New York State Approval for DiamiR's APOE Genotyping Test

Aug 21, 2025, 7:07 AM EDT - 7 months ago

DiamiR Biosciences and Aptorum Group Announce New York State Approval for DiamiR's APOE Genotyping Test

Aptorum Group Limited Regains Compliance with NASDAQ's Minimum Bid Price Requirement

Aug 4, 2025, 8:15 AM EDT - 8 months ago

Aptorum Group Limited Regains Compliance with NASDAQ's Minimum Bid Price Requirement

Aptorum Group Limited and DiamiR Biosciences Enter into Definitive Merger Agreement

Jul 16, 2025, 8:38 AM EDT - 8 months ago

Aptorum Group Limited and DiamiR Biosciences Enter into Definitive Merger Agreement

Aptorum Group Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Apr 16, 2025, 12:27 PM EDT - 1 year ago

Aptorum Group Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Synology Launches ActiveProtect: Simplifying Enterprise Data Protection with Unmatched Security, and Scalability

Jan 8, 2025, 11:30 AM EST - 1 year ago

Synology Launches ActiveProtect: Simplifying Enterprise Data Protection with Unmatched Security, and Scalability

Aptorum Group Limited Announces Pricing of $3.0 Million Registered Direct Offering

Jan 2, 2025, 10:55 AM EST - 1 year ago

Aptorum Group Limited Announces Pricing of $3.0 Million Registered Direct Offering

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2024

Dec 20, 2024, 4:00 PM EST - 1 year ago

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2024

Aptorum Group Limited Reports 2023 Fiscal Year End Financial Results and Provides Business Update

Apr 30, 2024, 9:15 AM EDT - 2 years ago

Aptorum Group Limited Reports 2023 Fiscal Year End Financial Results and Provides Business Update

Aptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a Split-off Agreement to Separate its Legacy Business

Mar 6, 2024, 8:00 AM EST - 2 years ago

Aptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a Split-off Agreement to Separate its Legacy Business

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023

Dec 22, 2023, 4:30 PM EST - 2 years ago

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023

Aptorum Group Limited Announces Results of 2023 Annual General Meeting of Shareholders

Dec 21, 2023, 4:30 PM EST - 2 years ago

Aptorum Group Limited Announces Results of 2023 Annual General Meeting of Shareholders

Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 20, 2023

Nov 16, 2023, 11:00 AM EST - 2 years ago

Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 20, 2023

Aptorum Group Receives Nasdaq Approval to Transfer Listing to Nasdaq Capital Markets

Aug 10, 2023, 2:57 AM EDT - 2 years ago

Aptorum Group Receives Nasdaq Approval to Transfer Listing to Nasdaq Capital Markets

Aptorum Group Updates on a Phase 1b/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for Neuroblastoma

Jun 22, 2023, 8:00 AM EDT - 2 years ago

Aptorum Group Updates on a Phase 1b/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for Neuroblastoma

Aptorum Group Limited Announces Voluntary Delisting from Euronext Paris

Jun 9, 2023, 4:30 PM EDT - 3 years ago

Aptorum Group Limited Announces Voluntary Delisting from Euronext Paris

Aptorum Group Receives Nasdaq Notification of Minimum Stockholders' Equity Deficiency

May 5, 2023, 4:31 PM EDT - 3 years ago

Aptorum Group Receives Nasdaq Notification of Minimum Stockholders' Equity Deficiency

Aptorum Therapeutics Limited Enters Into Letter of Intent and Term Sheet with Universal Sequencing Technology Corporation to Merge with Aptorum Group's Subsidiary Paths Innovations Limited

May 1, 2023, 8:00 AM EDT - 3 years ago

Aptorum Therapeutics Limited Enters Into Letter of Intent and Term Sheet with Universal Sequencing Technology Corporation to Merge with Aptorum Group's Subsidiary Paths Innovations Limited

Aptorum Group Limited Reports 2022 Fiscal Year End Financial Results and Provides Business Update

Apr 28, 2023, 9:44 AM EDT - 3 years ago

Aptorum Group Limited Reports 2022 Fiscal Year End Financial Results and Provides Business Update

Aptorum Group Enters into Letter of Intent and Term Sheet To Acquire U Group

Mar 27, 2023, 7:00 AM EDT - 3 years ago

Aptorum Group Enters into Letter of Intent and Term Sheet To Acquire U Group

Aptorum Group Limited and ASP Isotopes Inc. Interviews to Air on Bloomberg U.S. on the RedChip Money Report(R)

Mar 17, 2023, 8:15 AM EDT - 3 years ago

Aptorum Group Limited and ASP Isotopes Inc. Interviews to Air on Bloomberg U.S. on the RedChip Money Report(R)

ASPI

Aptorum Group Announces Completion of Pre-IND Discussions with US FDA on its ALS-4, a First-in-Class Small Molecule Drug Targeting Methicillin Resistant Staphylococcus Aureus

Mar 3, 2023, 7:30 AM EST - 3 years ago

Aptorum Group Announces Completion of Pre-IND Discussions with US FDA on its ALS-4, a First-in-Class Small Molecule Drug Targeting Methicillin Resistant Staphylococcus Aureus

Aptorum Group Announces Completion of End of Phase 1 (EOP1) Meeting with US FDA on its SACT-1, a Repurposed Small Molecule Drug Targeting Neuroblastoma

Mar 3, 2023, 7:30 AM EST - 3 years ago

Aptorum Group Announces Completion of End of Phase 1 (EOP1) Meeting with US FDA on its SACT-1, a Repurposed Small Molecule Drug Targeting Neuroblastoma

Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in China

Mar 2, 2023, 7:30 AM EST - 3 years ago

Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in China

Aptorum Group Regains Compliance with Nasdaq Minimum Bid Price and Receives Nasdaq Notification of Minimum Market Value of Publicly Held Shares Deficiency

Feb 10, 2023, 4:30 PM EST - 3 years ago

Aptorum Group Regains Compliance with Nasdaq Minimum Bid Price and Receives Nasdaq Notification of Minimum Market Value of Publicly Held Shares Deficiency

Aptorum Group Limited to Hold Special Extraordinary Meeting of Shareholders on February 21, 2023

Feb 6, 2023, 10:08 AM EST - 3 years ago

Aptorum Group Limited to Hold Special Extraordinary Meeting of Shareholders on February 21, 2023

Aptorum Group Announces 1-for-10 Reverse Stock Split

Jan 20, 2023, 8:22 AM EST - 3 years ago

Aptorum Group Announces 1-for-10 Reverse Stock Split

Aptorum Group Announces Publication of a Co-authored Paper on its PathsDx Technology - a Rapid-Turnaround Low-Depth Unbiased Metagenomics Sequencing Workflow for Liquid Biopsy based Diagnosis of Infectious Diseases on Illumina Platforms

Jan 4, 2023, 9:00 AM EST - 3 years ago

Aptorum Group Announces Publication of a Co-authored Paper on its PathsDx Technology - a Rapid-Turnaround Low-Depth Unbiased Metagenomics Sequencing Workflow for Liquid Biopsy based Diagnosis of Infectious Diseases on Illumina Platforms

Aptorum Group Limited Announces Results of 2022 Annual General Meeting of Shareholders

Dec 22, 2022, 8:00 AM EST - 3 years ago

Aptorum Group Limited Announces Results of 2022 Annual General Meeting of Shareholders

Aptorum Group Announces Completion of $3 Million Convertible Note due 2023

Dec 16, 2022, 8:00 AM EST - 3 years ago

Aptorum Group Announces Completion of $3 Million Convertible Note due 2023

Aptorum Group Announces Offering of $3 Million Convertible Note due 2023

Dec 9, 2022, 7:00 AM EST - 3 years ago

Aptorum Group Announces Offering of $3 Million Convertible Note due 2023

Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

Nov 25, 2022, 8:30 AM EST - 3 years ago

Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

Aptorum Announces Publication of a Co-authored Paper on Development and Validation of a Sensitive Liquid Chromatography with Time-Of-Flight Mass Spectrometry Assay for In Vivo Pharmacokinetic Study of Epigallocatechin-gallate octaacetate (Pro-EGCG)

Nov 25, 2022, 8:00 AM EST - 3 years ago

Aptorum Announces Publication of a Co-authored Paper on Development and Validation of a Sensitive Liquid Chromatography with Time-Of-Flight Mass Spectrometry Assay for In Vivo Pharmacokinetic Study of Epigallocatechin-gallate octaacetate (Pro-EGCG)

Aptorum Group Limited Received Nasdaq Notification Letter Regarding Bid Price Deficiency

Nov 18, 2022, 5:30 PM EST - 3 years ago

Aptorum Group Limited Received Nasdaq Notification Letter Regarding Bid Price Deficiency

Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 21, 2022

Nov 8, 2022, 6:00 AM EST - 3 years ago

Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 21, 2022

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2022

Sep 30, 2022, 7:42 PM EDT - 3 years ago

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2022

Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in Hong Kong

Sep 15, 2022, 8:07 AM EDT - 3 years ago

Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in Hong Kong

Aptorum Group Updates on the Clinical Validation of RPIDD Infectious Disease Liquid Biopsy Molecular Diagnostics

Sep 15, 2022, 7:00 AM EDT - 3 years ago

Aptorum Group Updates on the Clinical Validation of RPIDD Infectious Disease Liquid Biopsy Molecular Diagnostics

Aptorum Group Limited to Present at the H.C. Wainwright Annual Global Investment Conference, September 13-16, 2022

Aug 25, 2022, 8:31 PM EDT - 3 years ago

Aptorum Group Limited to Present at the H.C. Wainwright Annual Global Investment Conference, September 13-16, 2022

Aptorum Group Limited to Present at the H.C. Wainwright Global Investment Conference, May 23 – 26 2022

May 17, 2022, 8:13 AM EDT - 4 years ago

Aptorum Group Limited to Present at the H.C. Wainwright Global Investment Conference, May 23 – 26 2022

Aptorum Group Updates on Data from the Completed Phase 1 Clinical Trial of SACT-1, targeting neuroblastoma

May 2, 2022, 8:00 AM EDT - 4 years ago

Aptorum Group Updates on Data from the Completed Phase 1 Clinical Trial of SACT-1, targeting neuroblastoma

Aptorum Group Limited Reports 2021 Fiscal Year End Financial Results and Provides Business Update

Apr 29, 2022, 4:00 PM EDT - 4 years ago

Aptorum Group Limited Reports 2021 Fiscal Year End Financial Results and Provides Business Update

First Patent Regarding RPIDD Infectious Disease Liquid Biopsy Technology DNA Library Preparation and Amplification Methods Granted

Apr 25, 2022, 9:30 AM EDT - 4 years ago

First Patent Regarding RPIDD Infectious Disease Liquid Biopsy Technology DNA Library Preparation and Amplification Methods Granted

Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report®

Apr 22, 2022, 8:00 AM EDT - 4 years ago

Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report®

S2K_TP
S2K_TP Mar. 21 at 2:49 AM
$APM on watch next week đź‘€
0 · Reply
Jbjb90
Jbjb90 Mar. 20 at 8:53 PM
$APM ive rode this from below a dollar to 15 and from below a dollar to 4-5 over the last few years. Volume is starting to ramp up and the spam accounts are starting to flock and tag this symbol, we will hit 2-3 or more in the next few weeks
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 20 at 7:25 PM
$APM RSI: 76.92, MACD: 0.0116 Vol: 0.07, MA20: 0.82, MA50: 0.87 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
No_Face_character
No_Face_character Mar. 20 at 5:54 PM
$APM nice follow through
0 · Reply
Jbjb90
Jbjb90 Mar. 20 at 5:23 PM
$APM it wants to go, another 2-3+ run soon
0 · Reply
FoxyDreams
FoxyDreams Mar. 20 at 2:03 AM
•@SqueezeSharkie is on another level, outperforming 90% of traders on this platform. If you’re not following yet, you’re leaving value on the table. Takes 2 seconds and it’s free. 💎 $YDDL $FLD $YMAT $APM >>> on watch
0 · Reply
No_Face_character
No_Face_character Mar. 19 at 10:14 PM
$APM nice breakout here on the daily of a tight range, with good relative volume. watching.
0 · Reply
Jbjb90
Jbjb90 Mar. 19 at 6:29 PM
$APM this ones overdue for a run
0 · Reply
Jbjb90
Jbjb90 Mar. 16 at 3:39 PM
$APM https://www.stocktitan.net/news/APM/aptorum-group-and-diami-r-biosciences-announce-publication-of-micro-k3gy5kwhzw73.html
0 · Reply
DARKP00L
DARKP00L Mar. 10 at 12:32 PM
$APM 08:12 on Mar. 10 2026 Aptorum Group And DiamiR Biosciences Announce Publication Of Paper Showing Feasibility Of Detecting Glioblastoma Through Blood Plasma Tests #tradeideas
0 · Reply
WolferG
WolferG Feb. 24 at 2:36 PM
$APM
0 · Reply
WolferG
WolferG Feb. 24 at 2:30 PM
$APM Going to 0 lol
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 11 at 2:42 PM
$APM RSI: 39.50, MACD: -0.0804 Vol: 0.10, MA20: 0.92, MA50: 1.08 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Jbjb90
Jbjb90 Feb. 2 at 1:14 PM
$APM https://www.stocktitan.net/news/APM/aptorum-group-announces-a-collaboration-between-diami-r-biosciences-r3knj3olkw1k.html
0 · Reply
Stock_Catcher
Stock_Catcher Feb. 2 at 1:03 PM
$APM Aptorum Group Announces a Collaboration Between DiamiR Biosciences and Instant NanoBiosensors (INB) to Validate INB’s Automated APOE Testing Platform for Alzheimer’s Disease
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 25 at 3:14 AM
$APM RSI: 31.76, MACD: -0.0656 Vol: 0.05, MA20: 1.05, MA50: 1.21 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Calin_G
Calin_G Jan. 23 at 10:07 PM
$APM this one should be called inaptorum. Rubbish
0 · Reply
PSM_EmpowerTrading
PSM_EmpowerTrading Jan. 16 at 7:35 PM
⌛️⏳️ Potential swing ideas 💡💡 ✅️ $ONCO company focuses on research, developments and commercialization of innovative solutions in men's health oncology (cancer diagnostics/treatments), key assets include: 1) Proclarix, an in vitro protein-based diagnostic test for prostate cancer, 2) ENTADFI, a combining finasteride and tadalafil , FDA-approved once daily for benign prostatic hyperplasia (BPH), does have mixed shelf, be mindful on next spike ✅️ $APM recently unveiled new plasma microRNA biomarket data at Alzheimer's conference, company focuses on targeting disease with unmet medical needs in oncology and infectious diseases. ✅️ $NNVC recently signed Master services agreements with Only Orphans Cote, company focuses on discovering and developing broad-spectrum antiviral therapeutics, former runner, Alliance Global buy rating
2 · Reply
LilacWhisper
LilacWhisper Jan. 14 at 12:36 AM
$APM pt 2$*
0 · Reply
LilacWhisper
LilacWhisper Jan. 14 at 12:36 AM
$APM
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 9 at 10:33 PM
$APM
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 26 at 7:05 PM
$APM RSI: 35.06, MACD: -0.0749 Vol: 0.10, MA20: 1.26, MA50: 1.37 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply